Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

Biochemical Pharmacology

Volumn 72, Issue 10, 2006, Pages 1197-1206

  Waldmeier, Peter ^a   Bozyczko Coyne, Donna ^b   Williams, Michael ^b   Vaught, Jeffry L ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CEPHALON INC   (United States)

Author keywords

Animal models; Apoptosis; CEP 1347; Clinical trial failure; Necrosis; Parkinson's disease; TCH346

Indexed keywords

APOPTOSIS INHIBITOR; CEP 11004; CEP 1347; NEUROPROTECTIVE AGENT; SELEGILINE; TCH 346; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG TARGETING; HUMAN; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 33750207744     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.06.031     Document Type: Note

References (112)

1. Lockshin R.A., and Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nature Rev Mol Cell Biol 2 (2001) 545-550
2. Lockshin R.A., and Williams C.M. Programmed cell death. I. Cytology of degeneration in the intersegmental muscles of the Pernyi silkmoth. J Insect Physiol 11 (1965) 123-126
3. Lockshin R.A., and Williams C.M. Programmed cell death. IV. The influence of drugs on the breakdown of the intersegmental muscles of silkmoths. J Insect Physiol 11 (1965) 803-809
4. Kerr J.F., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 (1972) 239-257
5. Assuncao G.C., and Linden R. Programmed cell deaths. Apoptosis and alternative deathstyles. Eur J Biochem 271 (2004) 1638-1650
6. Bursch W. Multiple cell death programs: Charon's lifts to Hades. FEMS Yeast Res 5 (2004) 101-110
7. Kroemer G., Petit P., Zamzami N., Vayssière J.-L., and Mignotte B. The biochemistry of programmed cell death. FASEB J 9 (1995) 1277-1287
8. Rose C.D., and Henneberry R.C. Mechanisms of programmed cell death and their implications for the brain. Neurodegeneration 2 (1993) 287-298
9. Martin S.J., Green D.R., and Cotter T.G. Dicing with death: dissecting the components of the apoptosis machinery. Trends Biochem Sci 19 (1994) 26-30
10. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
11. Waldmeier P.C. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuro-Psychopharmacol Biol Psychiatr 27 (2003) 303-321
12. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124 (1994) 1-6
13. Bozyczko-Coyne D, Williams M. Neurodegenerative diseases. In: Williams M, editor. Comprehensive medicinal chemistry, 2nd ed., vol. 6, Elsevier, Oxford, in press.
14. Vaux D.L., and Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 93 (1996) 2239-2244
15. Schwartz L.M., and Milligan C.E. Cold thoughts of death: the role of ICE proteases in neuronal cell death. Trends Neurosci 19 (1996) 555-562
16. Chuang D.M., and Ishitani R. A role for GAPDH in apoptosis and neurodegeneration. Nature Med 2 (1996) 609-610
17. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57 (1994) 129-144
18. Yonish-Rouach E., Choisy C., Deguin V., Breugnot C., and May E. The role of p53 as a transcription factor in the induction of apoptosis (1996), Behring Institute Mitteilungen p. 60-71
19. Cosulich S., and Clarke P. Apoptosis: does stress kill?. Curr Biol 6 (1996) 1586-1588
20. Susin S.A., Zamzami N., and Kroemer G. The cell biology of apoptosis: evidence for the implication of mitochondria. Apoptosis 1 (1996) 231-242
21. Concha N.O., and Abdel-Meguid S.S. Controlling apoptosis by inhibition of caspases. Curr Med Chem 9 (2002) 713-726
22. Gudkov A.V., and Komarova E.A. Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 331 (2005) 726-736
23. Kuan C.Y., and Burke R.E. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets-Cns Neurol Dis 4 (2005) 63-67
24. Reed J.C. Apoptosis-based therapies. Nat Rev Drug Discov 1 (2002) 111-121
25. Kragten E., Lalande I., Zimmermann K., Roggo S., Schindler P., Müller D., et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273 (1998) 5821-5828
26. Mucke H.A. CEP-1347 (Cephalon). IDrugs 6 (2003) 377-383
27. Muck-Seler D., and Pivac N. TCH-346 (Novartis). IDrugs 3 (2000) 530-535
28. Hara M.R., Thomas B., Cascio M.B., Bae B.-L., Hester L.D., Dawson V.L., et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 103 (2006) 3887-3889
29. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 11 Suppl. 1 (2005) S3-S7
30. Schulz J.B., and Falkenburger B.H. Neuronal pathology in Parkinson's disease. Cell Tiss Res 318 (2004) 135-147
31. Przedborski S. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist 10 (2004) 1-7
32. Ankarcrona M., and Winblad B. Biomarkers for apoptosis in Alzheimer's disease. Int J Geriat Psychiatr 20 (2005) 101-105
33. Cotman C.W., Poon W.W., Rissman R.A., and Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol 64 (2005) 104-112
34. Hickey M.A., and Chesselet M.F. Apoptosis in Huntington's disease. Prog Neuro-Psychopharmacol Biol Psychiat 27 (2003) 255-265
35. Vis J.C., Schipper E., Boer-van Huizen R.T., Verbeek M.M., De Waal R.M.W., Wesseling P., et al. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol 109 (2005) 321-328
36. Waldmeier P.C., Boulton A.A., Cools A.R., Kato A.C., and Tatton W.G. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Trans 60 Suppl. (2000) 197-214
37. Eberhardt O., and Schulz J.B. Apoptotic mechanisms and anti-apoptotic therapy in the MPTP model of Parkinson's disease. Toxicol Lett 139 (2003) 135-151
38. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Mol Brain Res 134 (2005) 57-66
39. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/sto ry/05-11-2005/0003595559&EDATE
40. http://www.alsa.org/news/article.cfm?id=579&CFID=544070&CFTOKEN= 43868217
41. Ceballos-Baumann A.O. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. J Neurol 250 Suppl. 1 (2003) 15-23
42. http://phx.corporate-ir.net/phoenix.zhtml?c=81709&p=irol-newsArticle &ID=321884&highlight=
43. Mankoff S.P., Brander C., Ferrone S., and Marincola F.M. Lost in translation: obstacles to translational medicine. J Translation Med 2 (2004) 14-18
44. Fitzgerald G.A. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nature Rev Drug Discov 4 (2005) 815-818
45. Williams M. Enabling technologies in drug discovery: the technical and cultural integration of the new with the old. In: Moos WH, editor. Comp. Med. Chem. 2nd ed., vol. 2, Elsevier, Oxford, UK, in press.
46. Anon. What's in a name?. Nature Rev Drug Discov 4 (2006) 441
47. Samii A., Nutt J.G., and Ransom B.R. Parkinson's disease. Lancet 363 (2004) 1783-1793
48. Tolosa T., Wennin G., and Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 5 (2006) 75-86
49. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
50. Jakowec M.W., and Petzinger G.M. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 54 (2004) 497-513
51. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
52. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84 (2003) 491-502
53. LaPointe N., St Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 18 (2004) NIL629-NIL650
54. Vingerhoets F.J.G., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., and Calne D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 36 (1994) 765-770
55. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46 (1999) 598-605
56. Hirsch E.C., Hunot S., and Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 11 Suppl. 1 (2005) S9-S15
57. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. New Engl J Med 339 (1998) 1044-1053
58. 28K immunohistochemistry. Brain 122 (1999) 1421-1436
59. Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999) 1437-1448
60. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New Engl J Med 318 (1988) 876-880
61. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
62. Vila M., and Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4 (2003) 365-375
63. McGeer P.L., and McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10 Suppl. 1 (2005) S3-S7
64. Przedborski S., Tieu K., Perier C., and Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36 4 (2004) 375-379
65. Nagatsu T., Mogi M., Ichinose H., and Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl. (2000) 277-290
66. Ferrer I., Blanco R., Cutillas B., and Ambrosio S. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol Appl Neurobiol 26 (2000) 424-433
67. Hartmann A., Mouatt-Prigent A., Faucheux B.A., Agid Y., and Hirsch E.C. FADD: A link between TNF family receptors and caspases in Parkinson's disease. Neurol 58 (2002) 308-310
68. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann NY Acad Sci 991 (2003) 214-228
69. Hayley S., Crocker S.J., Smith P.D., Shree T., Jackson-Lewis V., Przedborski S., et al. Regulation of Dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 24 (2004) 2045-2053
70. Landau A.M., Luk K.C., Jones M.L., Siegrist-Johnstone R., Young Y.K., Kouassi E., et al. Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J Exp Med 202 (2005) 575-581
71. Rousselet E., Callebert J., Parain K., Joubert C., Hunot S., Hartmann A., et al. Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp Neurol 177 (2002) 183-192
72. Mladenovic A., Perovic M., Raicevic N., Kanazir S., Rakic L., and Ruzdijic S. 6-hydroxydopamine increases the level of TNFa and bax mRNA in the striatum and induces apoptosis of doparninergic neurons in hemiparkinsonian rats. Brain Res 996 (2004) 237-245
73. Mogi M., Togari A., Tanaka K., Ogawa N., Ichinose H., and Nagatsu T. Increase in level of tumor necrosis factor-a in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett 289 (2000) 165-168
74. Brancho D., Ventura J.J., Jaeschke A., Doran B., Flavell R.A., and Davis R.J. Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol Cell Biol 25 (2005) 3670-3681
75. Lemaire C., Andréau K., Souvannavong V., and Adam A. Inhibition of caspase activity induces a switch from apoptosis to necrosis. FEBS Lett 425 (1998) 266-270
76. Hartmann A., Troadec J.D., Hunot S., Kikly K., Faucheux B.A., Mouatt-Prigent A., et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21 (2001) 2247-2255
77. Edinger A.L., and Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16 (2004) 663-669
78. Lemasters J.J., Qian T., He L., Kim J.S., Elmore S.P., Cascio W.E., et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxidants Redox Signal 4 (2002) 769-781
79. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12 (1997) 25-31
80. Teismann P., and Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318 (2004) 149-161
81. Minghetti L., Ajmone-Cat M.A., De Berardinis M.A., and De Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res Rev 48 (2005) 251-256
82. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann NY Acad Sci 991 (2003) 214-228
83. Ferri K.F., and Kroemer G. Organelle-specific initiation of cell death pathways. Nature Cell Biol 3 (2001) E255-E263
84. Benn S.C., and Woolf C.J. Adult neuron survival strategies-slamming on the brakes. Nature Rev Neurosci 5 (2004) 686-700
85. Saporito M.S., Brown E.M., Miller M.S., and Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 288 (1999) 421-427
86. Konitsiotis S., Saporito M.S., Flood D.G., Hyland K., Miller M., Lin Y.G., et al. The neuroprotective effects of CEP-1347 in a primate model of MPTP-induced chronic progressive Parkinsonism. Soc Neurosci Abstr 25 (1999) 639.4
87. Ganguly A., Oo T.F., Rzhetskaya M., Pratt R., Yarygina O., Momoi T., et al. CEP11004, a novel inhibitor of the mixed lineage kinases, suppresses apoptotic death in dopamine neurons of the substantia nigra induced by 6-hydroxydopamine. J Neurochem 88 (2004) 469-480
88. Andringa G., van Oosten R.V., Unger W., Hafmans T.G., Veening J., Stoof J.C., et al. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. Eur J Neurosci 12 (2000) 3033-3043
89. Waldmeier P.C., Spooren W.P., and Hengerer B. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 362 (2000) 526-537
90. Andringa G., Eshuis S., Perentes E., Maguire R.P., Roth D., Ibrahim M., et al. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol Dis 14 (2003) 205-217
91. Hirsch E., Graybiel A.M., and Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
92. Kastner A., Hirsch E.C., Agid Y., and Javoy-Agid F. Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. Brain Res 606 (1993) 341-345
93. Kastner A., Herrero M.T., Hirsch E.C., Guillen J., Luquin M.R., Javoy-Agid F., et al. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy. Ann Neurol 36 (1994) 206-214
94. Maroney A.C., Finn J.P., Bozyczko-Coyne D., O'Kane T.M., Neff N.T., Tolkovsky A.M., et al. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J Neurochem 73 (1999) 1901-1912
95. Bozyczko-Coyne D., O'Kane T.M., Wu Z.L., Dobrzanski P., Murthy S., Vaught J.L., et al. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. J Neurochem 77 (2001) 849-863
96. Namgung U., and Xia Z. Arsenite-induced apoptosis in cortical neurons is mediated by c-Jun N-terminal protein kinase 3 and p38 mitogen-activated protein kinase. J Neurosci 20 (2000) 6442-6451
97. Maroney A.C., Glicksman M.A., Basma A.N., Walton K.M., Knight Jr. E., Murphy C.A., et al. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway. J Neurosci 18 (1998) 104-111
98. Bilsland J.G., and Harper S.J. CEP-1347 promotes survival of NGF responsive neurons in primary DRG explants. NeuroReport 14 (2003) 995-999
99. Harris C.A., Deshmukh M., Tsui-Pierchala B., Maroney A.C., and Johnson Jr. E.M. Inhibition of the c-Jun N-terminal kinase signaling pathway by the mixed lineage kinase inhibitor CEP-1347 (KT7515) preserves metabolism and growth of trophic factor-deprived neurons. J Neurosci 22 (2002) 103-113
100. Bodner A., Toth P.T., and Miller R.J. Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity. Exp Neurol 188 (2004) 246-253
101. Bodner A., Maroney A.C., Finn J.P., Ghadge G., Roos R., and Miller R.J. Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity. J Neurochem 82 (2002) 1424-1434
102. Harris C., Maroney A.C., and Johnson Jr. E.M. Identification of JNK-dependent and -independent components of cerebellar granule neuron apoptosis. J Neurochem 83 (2002) 992-1001
103. Muller G.J., Geist M.A., Veng L.M., Willesen M.G., Johansen F.F., Leist M., et al. A role for mixed lineage kinases in granule cell apoptosis induced by cytoskeletal disruption. J Neurochem 96 (2006) 1242-1252
104. Boll J.B., Geist M.A., Kaminski Schierle G.S., Petersen K., Leist M., and Vaudano E. Improvement of embryonic dopaminergic neurone survival in culture and after grafting into the striatum of hemiparkinsonian rats by CEP-1347. J Neurochem 88 (2004) 698-707
105. Lotharius J., Falsig J., van Beek J., Payne S., Dringen R., Brundin P., et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 25 (2005) 6329-6342
106. Mathiasen J.R., McKenna B.A., Saporito M.S., Ghadge G.D., Roos R.P., Holskin B.P., et al. Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells. Brain Res 1003 (2004) 86-97
107. Falsig J., Porzgen P., Lotharius J., and Leist M. Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol 173 (2004) 2762-2770
108. Glicksman M.A., Chiu A.Y., Dionne C.A., Harty M., Kaneko M., Murakata C., et al. CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. J Neurobiol 35 (1998) 361-370
109. Saporito M.S., Brown E.R., Carswell S., DiCamillo A.M., Miller M.S., Murakata C., et al. Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis. Neuroscience 86 (1998) 461-472
110. DiCamillo A.M., Neff N.T., Carswell S., and Haun F.A. Chronic sparing of delayed alternation performance and choline acetyltransferase activity by CEP-1347/KT-7515 in rats with lesions of nucleus basalis magnocellularis. Neuroscience 86 (1998) 473-483
111. Harper S.J., Saporito M.S., Hewson L., Young L., Smith D., Rigby M., et al. CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion. NeuroReport 11 (2000) 2271-2276
112. Pirvola U., Xing-Qun L., Virkkala J., Saarma M., Murakata C., Camoratto A.M., et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci 20 (2000) 43-50